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SCOPE AND PLAN OF WORK
Colorectal  cancer is  a very common malignancy in industrialized 
nations and a major cause of mortality and morbidity. Surgery, radiation 
therapy and chemotherapy are the three varieties of treatments commonly 
using for colorectal cancer. 5-Fluorouracil is one of the best drug of choice 
for colorectal cancer .It is also used for other types of malignancies such 
as breast cancer, head and neck cancer, because of its incomplete and 
erratic  oral  bioavailability.  5-Fluorouracil  commonly  administered 
intravenously,  however,  patients  are  showing more  compliance on oral 
dosage  forms  rather  than  intravenous  therapy,  with  oral  treatment 
potentially  more  easy  administration  and  less  costly.  The  regiments 
include  an  intravenous  bolus  or  continuous  infusion  of  5-Fluorouracil 
modulated with folinic acid (Leucovorin). On intravenous administration, 5-
Fluorouracil produces sever toxic effects of gastrointestinal, hematological, 
neural,  cardiac  and  dermatological  origin.  Site  specific  delivery  of  
5-Fluorouracil may reduce the systemic side effects and provide effective 
and  safe  therapy  of  colorectal  cancer  that  may  reduce  the  dose  and 
duration of therapy when compared with the conventional treatment.
The approaches to achieving colonic delivery of drugs include use 
of prodrugs, pH sensitive polymer coatings, time–dependent formulations, 
bacterial  degradable  coating,  and  time/pH-  controlled  colon  delivery 
capsules. A colon specific guar gum based tablet  of  5-Fluorouracil  has 
also been reported. However because of variations in transit throughout 
the colon, the drug release can be impaired when the colon-specific tablet 
matrix  is  not  readily disintegrated and treatment  will  remain ineffective. 
This problems could be circumvented by reducing, the size of the delivery 
carrier, since it has been reported that gastrointestinal retention depends 
upon the size of the carrier, meaning that smaller carrier will lead to longer 
residence in the colon.
In  recent  years,  the  interest  in  sub-  micron  systems 
(i.e.nanosystems)  in  pharmacy  has  urged.  This  is,  in  part,  due  to  the 
potential  advantage,  these  systems  provide  more  conventional  micro 
particulate  systems.  The challenges faced in  the  delivery  of  small  and 
large molecules such as poor solubility,  stability,  and limited absorption 
can  be  over  come  by  using  nanosystems.  Several  anticancer  drugs 
including  paclitaxel  and  doxorubicin  have  been  successfully  formulated 
using nanotechnology.
The pH- dependent  systems exploit  the generally  accepted view 
that pH of the human gastrointestinal tract increases progressively from 
the stomach (pH1-3), small intestine (pH6.5-7) to the colon (pH7-8). Most 
commonly  used  pH-dependent  coating  polymers  are  methacrylic  acid 
copolymers-.  Eudragit  RL  100  and  Eudragit  S  100  which  dissolve  at  
pH  5.5,  pH  6.0  and  pH  7.0  respectively.  The  use  of  Eudragit  RL100 
prevented drug release in the upper GI tract, during intestinal passage and 
permitted selective drug delivery in the colon.
The  present  investigation  involves  formulation,  characterization, 
vitro  release studies and colon targeting of  5-Fluorouracil  nanoparticles 
using Eudragit RL 100 for the treatment of colorectal cancer.
.
INTRODUCTION
Nanotechnology is the science of matter and material that deals 
with the particle size in nanometers. Nanoparticles are solid colloidal 
particles ranging in size from 1 to 1000 nm (1  µm) and composed of 
synthetic or semi synthetic polymers (Vyas, 2002). Nanoparticles were 
developed around 1970s.  They were  initially devised as carriers for 
vaccines  and  anticancer  drugs  (Lijima,1991).  In  order  to  enhance 
tumor uptake, the strategy of drug targeting was employed, and as a 
first important step, research focused on the development of methods 
to  reduce  the  uptake  of  the  nanoparticles  by  the  cells  of  the 
reticuloendothelial system (Edward, 2004). Nanoparticles were able to 
achieve, with success, tissue–targeting of many drugs. Nanoparticles 
are made up of non-biodegradable and biodegradable polymers.
The concept of drug targeting and controlled drug delivery can 
be achieved by surface modifications and choice of appropriate particle 
materials. Particles with magnetic characteristics can be retained at the 
target site by applying an external electromagnetic field. Nanoparticles 
composed of biodegradable polymers are proposed for application in 
oral  chemotherapy.  Nano  sized  micelles  are  of  advantage  for  drug 
transports with the narrow therapeutic indexes. Because of their small 
size,  nanoparticles  are  suitable  for  intravenous  administration. 
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Nanotechnology  is  being  employed  in  the  pharmaceutical  field  for 
many  reasons,  but  perhaps  the  leading  goals  are  to  improve  drug 
solubility/bioavailability  and/or  delivery  to  various  sites  of  action. 
Nanotechnology is also being employed to develop new and improved 
therapeutic devices. Nanotechnologies have already attracted over $3 
billion of global  government funding as part  of  efforts  to  enhance a 
range  of  disciplines  including  pharmaceuticals,  drug  delivery  and 
healthcare monitoring. Advances in nanomaterials, nanostructures and 
nanosystems  are  expected  to  drive  the  value  of  the  global 
nanotehnology market to over a trillion dollars by 2015. FDA is asking 
for  pharmaceutical  industry  input  to  help  the  Nanotechnology  Task 
Force refine its guidance recommendations. FDA wants advice on what 
characteristics  of  nanoparticles  to  consider  when  proving  the  safety 
and  effectiveness  of  products  containing  nanoscale  materials,  and 
circumstances that would change a product's regulatory status due to 
the use of nanotechnology. 
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APPLICATIONS
Applications of nanotechnology in the different field can be summarized as 
follows:
Nanomedicines:  Nanodrugs,  medical  devices,  tissue  engineering, 
etc.Chemicals and cosmetics: Nanoscale chemicals and compounds, paints, coating, 
etc.
Materials: Nanoparticles, carbon nanotubes, biopolymers, paints, coating.
Food science: Processing, nutraceutical food, nanocapsules
Envirnoment and energy: Water and air purification filters, fuel cells, photovoltics.
Military and security: Biosensers, weapons, sensory enhancement.
Electronics:  Semiconductor  chips,  memory  storage,  photonics, 
optoelectronics.
Scientific  tools:  Atomic  force,  microscopes  and  scanning  tunneling 
microscope.
Agriculture: Pesticides, food production
CLASSIFICATION OF NANOPARTICLES
In one dimensions (Thin surface coatings)
One-dimensional systems, such as thin films or manufactured surfaces.
1. In two dimensions
a) Carbon nanotubes
Carbon nanotubes are a new form of carbon molecule. Bound in a hexagonal 
network of carbon atoms, these hollow cylinders can have diameters as small as 0.7 
nm and reach several millimeters in length . Each end can be opened or closed by a 
fullerene half-molecule. These nanotubes can have a single layer (like a straw) or 
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several  layers  (like  a  poster  rolled  in  a  tube)  of  coaxial  cylinders  of  increasing 
diameters in a common axis.
2. In three dimensions
a) Fullerenes (Carbon 60)
Fullerenes are spherical cages containing from 28 to more than 100 carbon 
atoms. Fullerenes are a class of materials displaying unique physical properties. They 
can be subjected to  extreme pressures and regain  their  original  shape when the 
pressure is released. These molecules do not combine with each other, thus giving 
them major potential for application as lubricants.
b) Dendrimers
Dendrimers  represent  a  new  class  of  controlled-structure  polymers  with 
nanometric dimensions.  They are considered to be basic elements for large-scale 
synthesis of organic and inorganic nanostructures with dimensions of 1 to 100 nm, 
displaying unique properties. Compatible with organic structures such as DNA, they 
can also be fabricated to interact  with  metallic  nanocrystals  and nanotubes or  to 
possess an encapsulation capacity (Tomalia, 2004)
c) Quantum dots
It  represents a special  form of  spherical  nanocrystals from 1 to 10 nm in 
diameter.  They  have  been  developed  in  the  form  of  semiconductors,  insulators, 
metals, magnetic materials or metallic oxides. 
3. Advantages of nanoparticles
• Increased bioavailability
• Dose proportionality
• Decreased toxicity
• Smaller dosage form (i.e., smaller tablet)
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• Stable dosage forms of drugs which are either unstable or have 
unacceptably low bioavailability in non-nanoparticulate dosage 
forms.
• Increased  active  agent  surface  area  results  in  a  faster 
dissolution of the active agent in an aqueous environment, such 
as the human body.  Faster dissolution generally equates with 
greater bioavailability, smaller drug doses, less toxicity.
• Reduction in fed/fasted variability (Edward, 2004)
NANOPARTICLE PRODUCTION PROCESSES
Nanoparticles can be produced by either dispersion-based processes (which 
involves  breaking  larger  micrometer-sized  particles  into  nanoparticles)  or 
precipitation-based processes.
Dispersion-based processes
a) Wet milling
Wet milling is an attrition-based process in which the drug is dispersed first in 
an aqueous-based surfactant solution. The resulting suspension is subjected to wet 
milling using a pearl mill in the presence of milling media.
b) High-pressure homogenization
High-pressure homogenization is based on the principle of cavitation (i.e., the 
formation, growth, and implosive collapse of vapor bubbles in a liquid. In this process, 
a  drug  presuspension  (containing  drug  in  the  micrometer  range)  is  prepared  by 
subjecting the drug to air jet milling in the presence of an aqueous surfactant solution.
The main advantage of high-pressure homogenization is that it is suitable for 
both large and laboratory-scale production because high-pressure homogenizers are 
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available in various sizes. In addition, homogenization creates negligible nanoparticle 
contamination,  which  is  one  of  the  most  important  objectives  of  a  nanoparticle 
production process.
A limitation of this process is that the pressure used is so high that in some 
cases, the crystal structure changed.
c) Emulsification technology
Emulsification also can be used to prepare nanoparticle suspensions. In this 
method, the drug solution in an organic solvent is dispersed in the aqueous phase 
containing  surfactant.  This  step is  followed by the  evaporation of  organic  solvent 
under reduced pressure, which results in the precipitation of drug particles to form a 
nanoparticle suspension which is stabilized by the added surfactant. 
PRECIPITATION-BASED PROCESSES
a) Spray freezing into liquid (SFL)
In this process, developed at the University of Texas at Austin (Austin, TX) 
and commercialized by Dow Chemical Company (Midland, MI), an aqueous, organic, 
or  aqueous–organic  co-solvent  solution;  aqueous–organic  emulsion;  or  drug 
suspension is atomized into a cryogenic  liquid  such as liquid nitrogen to produce 
frozen  nanoparticles  which  are  subsequently  lyophilized  to  obtain  free  flowing 
powder.
b) Evaporative precipitation into aqueous solution (EPAS)
The EPAS process also was developed by the University of Texas at Austin 
and commercialized by Dow Chemical Company. In this process, the drug solution in 
a low boiling liquid organic solvent is heated under pressure to a temperature above 
the solvent's normal boiling point and then atomized into a heated aqueous solution 
containing stabilizing surfactant.
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c) Rapid expansion from a liquefied-gas solution (RESS)
In  an  RESS  process,  a  solution  or  dispersion  of  phospholipids  or  other 
suitable surfactant in the supercritical fluid is formed. Then, rapid nucleation of drug is 
induced in  the  supercritical  fluid  containing  surfactant.  This  process  allows  rapid, 
intimate contact of the drug dissolved in supercritical fluid and the surfactant which 
inhibits the growth of the newly formed particles.
d) Precipitation with a Compressed Fluid Antisolvent (PCA)
In  the  PCA  process  (patented  by  RTP  Pharmaceuticals  and  licensed  to 
SkyePharma Plc.,  London, UK), supercritical  carbon dioxide is mixed with organic 
solvents containing drug compounds. The solvent expands into supercritical carbon 
dioxide,  thus increasing  the concentration of  the  solute  in  the  solution,  making it  
supersaturated, and causing the solute to precipitate or crystallize out of solution.
Parameter Characterization method(s)
Particle size and size 
distribution
Photon electron spectroscopy
Laser defractometry
Transmission electron microscopy
Scanning electron microscopy
Atomic force microscopy
Charge determination Laser doppler anemomometry
Zeta potentiometer
Surface 
hydrophobicity
Water contact angle measurements
Rose Bengal (dye) binding
Hydrophobic interaction chromatography
X-ray photoelectron spectrometry
Chemical analysis of 
surface
Static secondary ion mass spectrometry, sorptometer
Carrier-drug 
interaction
Differential scanning calorimetry
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Nanoparticle 
dispersion stability
Critical flocculation temperature
Release profile In vitro release characteristics under physiological and sink 
condition
Drug stability Bioassay of drug extracted from nanoparticles
Chemical analysis of drug
HEALTH IMPLICATIONS OF NANOPARTICLES
It  is important  to differentiate between ‘free’  and ‘fixed’  nanoparticles. The 
former pose a more direct health threat because they are more difficult to contain,  
easily become airborne and can be inhaled.
Nanoparticles  can  enter  the  human  body  in  several  ways;
(i) via the lungs where a rapid translocation through the blood stream to vital organs 
is possible, including crossing the BBB, and absorption by (ii) the intestinal tract, or 
(iii) the skin.
a) Skin
Particles  500–1000  nm  in  size,  theoretically  beyond  the  realms  of 
nanotechnology, can penetrate and reach the lower levels of human skin, 128 and 
smaller particles are likely to move deeper into the skin. TiO2 particles are often used 
in sunscreens to absorb UV light and therefore to protect skin against sunburn or 
genetic damage. Micrometer-sized particles of TiO2 get through the human stratum 
corneum and even into some hair follicles – including their deeper parts. (Lademann 
et al., 1999).
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b) Intestinal tract
The  epithelium  of  the  small  and  large  intestines  is  in  close  contact  with 
ingested  material  so  that  nutrients  can  be  utilized.  
A mixture of disaccharides, peptides, fatty acids, and monoglycerides generated by 
digestion in small intestine are further transformed and taken in the villi.
The kinetics of particle translocation in the intestine depends on diffusion and 
accessibility  through  mucus,  initial  contact  with  enterocyte  or  M-cell,  cellular 
trafficking, and post-translocation events.
Charged particles, such as carboxylated polystyrene nanoparticles or those 
composed of  positively  charged  polymers  exhibit  poor  oral  bioavailability  through 
electrostatic repulsion and mucus entrapment. The smaller the particle diameter the 
faster  they  could  permutate  the  mucus  to  reach  the  colonic  enterocytes;  14  nm 
diameter permeated within 2 minutes, 415 nm particles took 30 minutes, while 1000 
nm particles were unable to translocate this barrier 
c) Lung
Based on three particle-types titanium dioxide (TiO2), carbon black, hazard 
studies in rats demonstrated that ultrafine or nanoparticles administered to the lung 
produce more potent  adverse effects in the form of inflammation and subsequent 
tumors  compared  with  larger  sized  particles  of  identical  chemical  composition  at 
equivalent mass concentrations or intratracheally-instilled doses. Surface properties, 
such  as  surface  chemistry  and  area,  may  play  a  significant  role  in  nanoparticle 
particle toxicity.
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CLINICAL ASPECTS
Several  nanoparticle  technologies are currently  in  clinical  trials  and a few 
have  progressed  to  clinical  use.  NanoCrystal™  technology  from  Elan 
Pharmaceuticals  International  Ltd.  is  one  breakthrough  technology  that  is  being 
licensed  to  pharmaceutical  companies  for  specialized  drug  delivery  systems. 
Currently, there are some FDA approved drug products employing this technology. 
Rapamune (Wyeth-Ayerst  Laboratories),  an  oral  tablet  dosage  form  containing 
nanoparticles of the immunosuppressant drug Rapamycin, was approved by the U.S. 
FDA
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COLON
The large intestine is about 1.5 meters long, beginning at the 
caecum in the right iliac fossa and terminating at the rectum and anal 
canal  deep in  the  pelvis.  Its  lumen is  larger  than  that  of  the  small 
intestine.  It  forms  an  arch  round  the  coiled–up  small  intestine.  For 
descriptive purposes the colon is divided into the caecum, ascending 
colon,  transverse  colon,  descending  colon,  sigmoid  or  pelvic  colon, 
rectum and anal canal.
The caecum is the first part of the colon. It is a dilated portion 
which has a blind end inferiorly and is continuous with the ascending 
colon superiorly. The vermiform appendix is a fine tube closed at one 
end, which leads from the caecum. It is usually about 13 cm long and 
has the same structure as the walls of the colon but contains more 
lymphoid tissue.
The ascending colon passes upwards from the caecum to the 
level of the liver where it bends acutely to the left at the hepatic flexure 
(right colic flexure) to become the transverse colon.
The transverse colon is a loop of colon which extends across 
the abdominal cavity in front of the duodenum and the stomach to the 
area of the spleen where it forms the splenic flexure (left colic flexure) 
by bending acutely downwards to become the ascending colon.
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The  descending  colon  passes  down  the  left  side  of  the 
abdominal cavity curves towards the midline. After it  enters the true 
pelvis it is known as the sigmoid or pelvic colon.
The rectum is a slightly dilated part of the colon which is about 
13 cm long. It leads from the sigmoid colon and terminates in the anal 
canal.
The anal canal is a short canal about 3.8 cm long in the adult 
and leads from the rectum to  the  exterior.  There are  two sphincter 
muscles which control  the anus; the internal  sphincter,  consisting of 
stomach muscle fibers, is under the control of the autonomic nervous 
system and the external sphincter, formed by striated muscle, is under 
voluntary nerve control.
Fig. 1 Anatomy of large Intestine
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ANATOMY OF COLON
The colon is mainly situated in the abdomen. It is a cylindrical 
tube which is lined by a moist, soft pink lining called the mucosa; the 
pathway  is  called  the  lumen  and  is  approximately  2-3  inches  in 
diameter. The colon form the lower part of the gastrointestinal tract and 
extends from the ileocaecal junction to the anus .The colon is upper 
five feet of the large intestine and the rectum is the lower six inches. 
The junction of the small intestine (ileum) and the colon is in the lower 
right  abdomen. The next  portion of  the colon, in the order in which 
contents flow, is the angle or bend is known as the hepatic flexure, 
located  just  beneath  the  rib  cage.  The  colon  then  turns  to  a  long 
horizontal segment, the transverse colon, beneath the left rib cage, the 
colon turns downward at the splenic flexure, to become the descending 
(distal) colon. In the left lower portion of the abdomen, the colon makes 
an S-shaped curve from the hip over the midline known as sigmoid 
colon. Lymph nodes are structures found in the circulating lymphatic 
system of the body that produce and store cells that fight infection, 
inflammation, foreign proteins and cancer.
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PHYSIOLOGY
Approximately 500 ml of food pass through the colon daily. The 
various sections of the digestive tract absorb and remove water, propel 
waste throughout the long system of muscular tubes, work to keep the 
body  alkalized,  and  accommodate  the  colonization  of  billions  of 
beneficial microorganisms to aid us in breaking down waste matter.
BLOOD SUPPLY
Arterial supply is mainly by the superior and inferior mesenteric 
arteries.  The  sigmoid  mesenteric  artery  supplies  the  caecum, 
ascending and most of the transverse colon. The inferior mesenteric 
artery supplies the remainder of the colon and the proximal part of the 
rectum. The distal of the rectum and the anus are supplied by branches 
from  the  internal  iliac  arteries.  Venous  drainage  is  mainly  by  the 
superior and inferior mesenteric veins which drain blood from the parts 
supplied by arteries of the same names. These veins join the splenic 
and gastric veins to form the portal vein. Veins draining the distal part 
of the rectum and the anus join the internal iliac veins.
COLONIC MICROFLORA
The slow movement of material through the colon allows a large 
microbial population to thrive there. Over 400 distinct bacterial species 
have been found, 20-30% of which are of the genus bacteroids. Most 
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of these isolated bacteria are anaerobic in nature; a small number of 
fungi are also present. The rate of microbial growth is greatest in the 
proximal areas because of high concentration of energy source. The 
principal  sources  of  nutrition  for  the  colonic  microorganisms  are 
carbohydrates are arriving in intestinal chime. The carbohydrates are 
degraded by the action of polysaccharides and glycosidase enzymes 
and the ultimate products of fermentation are short chain fatty acids, 
carbon  dioxide,  hydrogen,  methane  and  hydrogen  sulphide.  In  the 
proximal regions of the colon, carbohydrate fermentation predominates 
and results in a relatively low pH. In the distal regions, there is little 
carbohydrate fermentation, resulting in a higher pH. The bacteria within 
the  colon  are  predominantly  anaerobic  and  there  is  a  low  redox 
potential (reducing environment).
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REGION OF 
GASTROINTESTINAL TRACT CHARACTERISTICS
Large intestine Length in cm
Caecum 6-7
Ascending colon 20
Transverse colon 45
Descending colon 30
Sigmoid colon 40
Rectum 12
Anal canal 3
Large intestine Intestinal diameter (cm)
pH of Caecum and colon 5.5-7
Rectum 7
Colon Redox potential
Right -415
Mid -400
Left -380
FUNCTIONS
The  major  function  of  the  colon  is  the  consolidation  of  the 
intestinal  contents  into  faeces  by  the  absorption  of  water,  and 
electrolytes  and  to  store  the  faeces  until  excretion.  The  absorption 
capacity is very high; each day about 2000 ml of fluid enters the colon 
through the ileocaecal valve from which more than 90% of the fluid is 
absorbed. In the healthy human colon, sodium and chloride ions are 
usually  secreted.  On  average,  it  has  been  estimated  that  colon 
contains only about 220g of wet material (Sarasija et al., 2000)
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CANCER
Cancer is a group of more than 100 different diseases. They affect the body's 
basic unit, the cell. Cancer occurs when cells become abnormal and divide without 
control or order. Like all other organs of the body, the colon and rectum are made up 
of many types of cells. Normally, cells divide to produce more cells only when the 
body needs them. This orderly process helps keep us healthy.
If cells keep dividing when new cells are not needed, a mass of tissue forms. 
This mass of extra tissue, called a growth or tumor, can be benign or malignant.
Benign tumors are not cancer. They can usually be removed and, in most 
cases,  they do not  come back.  Most  important,  cells  from benign  tumors do not 
spread to other parts of the body. Benign tumors are rarely a threat to life.
Malignant tumors are cancer. Cancer cells can invade and damage tissues 
and organs near the tumor.  Also,  cancer cells  can break away from a malignant 
tumor and enter the bloodstream or lymphatic system. This is how cancer spreads 
from the original (primary) tumor to form new tumors in other parts of the body. The 
spread of cancer is called metastasis.
When cancer spreads to another part of the body, the new tumor has the 
same kind of abnormal cells and the same name as the primary tumor. For example, 
if colon cancer spreads to the liver, the cancer cells in the liver are colon cancer cells.  
The disease is metastatic colon cancer (it is not liver cancer).
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COLON CANCER
Globally,  cancer  of  the colon and rectum is  the third  leading 
cause of cancer in males and the fourth leading cause of cancer in 
females. The frequency of colorectal cancer varies around the world. It 
is  common in  the  Western world  and is  rare  in  Asia and Africa.  In 
countries where the people have adopted western diets, the incidence 
of colorectal cancer is increasing.
Colorectal cancer, also called colon cancer or large bowel cancer, includes 
cancerous growths in the colon, rectum and appendix With 655,000 deaths worldwide 
per year, it is the third most common form of cancer and the second leading cause of 
cancer-related death in the Western world. Many colorectal cancers are thought to 
arise  from  adenomatous  polyps  in  the  colon.  These  mushroom-like  growths  are 
usually benign, but some may develop into cancer over time. The majority of the time, 
the diagnosis of localized colon cancer is through colonoscopy. Therapy is usually 
through surgery, which in many cases is followed by chemotherapy.
The colon is the part of the digestive system where the waste 
material is stored. The rectum is the end of the colon adjacent to the 
anus.  Together,  they  form  a  long,  muscular  tube  called  the  large 
intestine (also known as the large bowel).  Tumors of the colon and 
rectum are growths arising from the inner wall of the large intestine. 
Benign  tumors  of  the  large  intestine  are  called  polyps.  Malignant 
tumors of the large intestine are called cancers.
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Benign polyps do not invade nearby tissue or spread to other 
parts  of  the  body.  Benign  polyps  can  be  easily  removed  during 
colonoscopy and  are  not  life-threatening.  If  benign  polyps  are  not 
removed  from  the  large  intestine,  they  can  become  malignant 
(cancerous) over time.
Most of the cancers of the large intestine are believed to have 
developed from polyps. Cancer of the colon and rectum (also referred 
to as colorectal cancer) can invade and damage adjacent tissues and 
organs. Cancer cells can also break away and spread to other parts of 
the body (such as liver and lung) where new tumors form. The spread 
of  colon  cancer  to  distant  organs  is  called  metastasis  of  the  colon 
cancer. Once metastasis has occurred in colorectal cancer, a complete 
cure of the cancer is unlikely.
Fig. 2  Colon Cancer
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SYMPTOMS
The first symptoms of colon cancer are usually vague, like bleeding, weight 
loss, and fatigue (tiredness). Local (bowel) symptoms are rare until  the tumor has 
grown to a large size. Generally, the nearer the tumor is to the anus, the more bowel 
symptoms there will be.
Symptoms and signs are divided into local, constitutional and metastatic
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LOCAL SYMPTOMS
• Change in bowel habits
o Change  in  frequency of  movements  (constipation/or 
diarrhoea)
o Feeling  of  incomplete  defecation  (tenesmus)  and 
reduction in diameter of stool, both characteristic of rectal 
cancer,
o Change in the appearance of stools:
 Bloody stool  s   or rectal bleeding
 Stools with mucus
 Black, tar-like stool (melena), more likely related to 
upper gastrointestinal  e.g.  stomach or duodenal 
disease
• Bowel obstruction   causing bowel pain, bloating and vomiting of 
stool-like material.
• A tumor in the abdomen, felt by patients or their doctors.
• Symptoms  related  to  invasion  by  the  cancer  of  the  bladder 
causing hematuria (blood in the urine) or pneumaturia (air in the 
urine),  or  invasion  of  the  vagina causing  maloderous vaginal 
discharge. These are late events, indicative of a large tumor.
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CONSTITUTIONAL (SYSTEMIC) SYMPTOMS
• Unexplained weight loss is a worrying symptom caused by lack 
of  appetite and  systemic  effects  of  a  malignant  growth. 
However,  weight  loss  is  not  as  much  a  feature  of  colorectal 
cancer as it is of other cancers (e.g. oesophageal carcinoma).
• Anemia,  causing dizziness,  fatigue and palpitations. Clinically, 
there  will  be  pallor and  blood  tests  will  confirm  the  low 
hemoglobin level.
METASTATIC SYMPTOMS
• Liver metastases, causing:
o Jaundice  
o Pain  in  the  abdomen,  more  often  the  upper  part  of 
epigastrium or right side of the abdomen
o liver enlargement  , usually felt by a doctor
• Blood clots   in the veins and arteries, a paraneoplastic syndrome 
related  to  hypercoagulability  of  the  blood  (the  blood  is 
"thickened").
TREATMENT
The treatment depends on the staging of the cancer. When colorectal cancer 
is caught at early stages (with little spread) it can be curable. However when it is 
detected at later stages (when distant metastases are present) it is less likely to be 
curable.
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Surgery  remains  the  primary  treatment  while  chemotherapy  and/or 
radiotherapy may be recommended depending on the individual patient's staging and 
other medical factors.
SURGERY
Surgeries can be categorised into curative, palliative, bypass, fecal diversion, 
or open-and-close.
Curative Surgical treatment can be offered if the tumor is localized.
• Very  early  cancer  that  develops  within  a  polyp  can often  be 
cured by removing the polyp (i.e., polypectomy) at the time of 
colonoscopy.
• In  colon  cancer,  a  more  advanced  tumor  typically  requires 
surgical  removal  of  the section of  colon containing the tumor 
with  sufficient  margins,  and  radical  en-bloc  resection  of 
mesentery  and lymph nodes to  reduce  local  recurrence (i.e., 
colectomy).  If  possible,  the  remaining  parts  of  colon  are 
anastomosed together to create a functioning colon. In cases 
when anastomosis is not possible, a stoma (artificial orifice) is 
created.
• Curative  surgery  on  rectal  cancer  includes  total  mesorectal 
excision (lower anterior resection) or abdominoperineal excision. 
In  case  of  multiple  metastases,  palliative  (non  curative)  resection  of  the 
primary tumor is still  offered in order to reduce further morbidity caused by tumor 
bleeding,  invasion,  and  its  catabolic  effect.  Surgical  removal  of  isolated  liver 
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metastases is, however, common and may be curative in selected patients; improved 
chemotherapy has increased the number of patients who are offered surgical removal 
of isolated liver metastases.
If  the  tumor  invaded  into  adjacent  vital  structures  which  makes  excision 
technically  difficult,  the  surgeons may prefer  to  bypass  the  tumor  (ileotransverse 
bypass) or to do a proximal fecal diversion through a stoma.
The worst case would be an open-and-close surgery, when surgeons find the 
tumor unresectable and the small bowel involved;  any more procedures would do 
more  harm  than  good  to  the  patient.  This  is  uncommon  with  the  advent  of 
laparoscopy and better radiological imaging. Most of these cases formerly subjected 
to "open and close" procedures are now diagnosed in advance and surgery avoided.
Laparoscopic-assisted colectomy is a minimally-invasive technique that can 
reduce the size of the incision and may reduce post-operative pain.
As  with  any  surgical  procedure,  colorectal  surgery  may  result  in 
complications including
• wound infection, dehiscence (bursting of wound) or hernia
• anastomosis breakdown, leading to abscess or fistula formation, 
and/or peritonitis
• bleeding with or without hematoma formation
• adhesions resulting in bowel obstruction (especially small bowel)
• adjacent  organ  injury;  most  commonly  to  the  small  intestine, 
ureters, spleen, or bladder
• cardiorespiratory  complications  such  as  myocardial  infarction, 
pneumonia, arrythmia, pulmonary embolism etc
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CHEMOTHERAPY
Chemotherapy  is  used  to  reduce  the  likelihood  of  metastasis  developing, 
shrink tumor size, or slow tumor growth. Chemotherapy is often applied after surgery 
(adjuvant), before surgery (neo-adjuvant), or as the primary therapy (palliative). The 
treatments listed here have been shown in clinical trials to improve survival and/or 
reduce mortality rate and have been approved for use by the US Food and Drug 
Administration. In colon cancer, chemotherapy after surgery is usually only given if 
the cancer has spread to the lymph nodes (Stage III).
• Adjuvant (after  surgery)  chemotherapy.  One regimen involves 
the  combination  of  infusional  5-Fluorouracil  leucovorin,  and 
oxaliplatin (FOLFOX)
o 5-fluorouracil (5-FU) or Capecitabine (Xeloda) 
o Leucovorin (LV, Folinic Acid) 
o Oxaliplatin (Eloxatin) 
• Chemotherapy for metastatic disease. Commonly used first line 
chemotherapy regimens involve the combination of infusional  
5-Fluorouracil,  leucovorin  and  oxaliplatin  (FOLFOX  with 
bevacizumab  or  infusional  5-Fluorouracil,  leucovorin,  and 
irinotecan (FOLFIRI) with bevacizumab.
o 5-Fluorouracil (5-FU) or Capecitabine
o UFT or Tegafur-uracil
o Leucovorin (LV, Folinic Acid) 
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o Irinotecan (Camptosar) 
o Oxaliplatin (Eloxatin)
o Bevacizumab (Avastin)
o Cetuximab (Erbitux)
o Panitumumab (Vectibix)
• In clinical trials for treated/untreated metastatic disease.
o Bortezomib (Velcade)
o Oblimersen (Genasense, G3139)
o Gefitinib and Erlotinib (Tarceva)
o Topotecan (Hycamtin)
RADIATION THERAPY
Radiotherapy  is  not  used  routinely  in  colon  cancer,  as  it  could  lead  to 
radiation enteritis, and it is difficult to target specific portions of the colon. It is more 
common for radiation to be used in rectal cancer, since the rectum does not move as 
much as the colon and is thus easier to target. Indications include:
COLON CANCER
• Pain relief and palliation - targeted at metastatic tumor deposits 
if they compress vital structures and/or cause pain
RECTAL CANCER
o neoadjuvant  -  given  before  surgery  in  patients  with 
tumors  that  extend  outside  the  rectum  or  have  spread  to 
regional  lymph  nodes,  in  order  to  decrease  the  risk  of 
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recurrence following surgery or to allow for less invasive surgical 
approaches  (such  as  a  low  anterior  resection  instead  of  an 
abdomino-perineal resection). 
o adjuvant  -  where  a  tumor  perforates  the  rectum  or 
involves regional lymph nodes palliative - to decrease the tumor 
burden in order to relieve or prevent symptoms. 
Sometimes chemotherapy agents are used to increase the effectiveness of 
radiation by sensitizing tumor cells if present.
IMMUNOTHERAPY
Bacillus Calmette-Guérin (BCG) is being investigated as an adjuvant mixed 
with autologous tumor cells in immunotherapy for colorectal cancer.
VACCINE
In November 2006, it was announced that a vaccine had been developed and 
tested with very promising results. The new vaccine, called TroVax works in a totally 
different way to existing treatments by harnessing the patient's own immune system 
to  fight  the disease.  Experts  say  this  suggests  that  gene therapy vaccines could 
prove an effective treatment for a whole range of cancers. Oxford Bio Medica is a 
British spin-out from Oxford University specialising in the development of gene-based 
treatments Phase III  trials  are  underway for  renal  cancers and planned for  colon 
cancers.
30
APPROACHES  TO  COLONIC  DRUG  DELIVERY  VIA  THE  ORAL 
ROUTE
The  challenge  of  targeting  drugs  specifically  to  the  colonic 
region of the gastrointestinal tract is one that has been embraced by 
scientists over the past two decades. The colon has recently become 
accepted as an increasingly important site for drug delivery. Research 
interest in the area of colonic drug delivery has been fuelled by the 
need to better treat pathologies of the colon that range in seriousness 
from constipation and diarrhoea to the debilitating inflammatory bowel 
diseases  (ulcerative  colitis  and  Crohn’s  disease)  through  to  colon 
carcinoma, the third most prevalent form of cancer in both men and 
women. Targeted drug delivery to the colon would therefore ensure 
direct treatment at the disease site, lower dosing and a reduction in 
systemic side effects. Aside from local treatment, the colon can also be 
utilized as a portal for the entry of drugs into the blood stream for the 
purpose of systemic therapy. Drugs that are degraded and /or poorly 
absorbed in  the upper  gut  may be preferentially  absorbed from the 
colon because of the lower  levels  of  luminal  and mucosal  digestive 
enzymes, as compared with the small intestine .Further more, colonic 
drug delivery may also be used as a means of achieving chronotherapy 
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for diseases that are sensitive to circulation rhythms, such as asthma 
and arthritis.
Many  proteins  and  peptide  drugs  like  insulin  cannot  be 
administered through the oral route because of their degradation by the 
digestive enzymes of the stomach and the small intestine. Delivery of 
the  drugs  to  the  systemic  circulation  through  colonic  absorption 
represents  a  novel  mode  of  introducing  peptides  and  protein  drug 
molecules and drugs that absorb poorly from the upper gastrointestinal 
tract as the colon lacks various digestive enzymes present in the upper 
GIT. The drug targeting through colon not only reduces the dose to be 
administered  but  also  reduces  the  incidence  of  possible  adverse 
effects  associated  with  these  chemotherapeutic  agents  
(Sinha et al., 2001).
The various strategies for targeting orally administered drugs to 
the colon include covalent linkage of a drug with a carrier, coating with 
pH-sensitive  polymers,  formulation  of  timed  released  systems, 
exploitation  of  carriers  that  are  degraded  specifically  by  colonic 
bacteria,  bioadhesive  systems  and  osmotic  controlled  drug  delivery 
systems. Various prodrugs (sulfasalazine, ipsalazine, balsalazine and 
olsalazine)  have been developed that  are aimed to  deliver  5-Amino 
salicylic  acid  (5-ASA)  for  localized  chemotherapy  of  inflammatory 
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bowel disease (IBD). Microbially degradable polymers especially azo 
crosslinked polymers  have been investigated for  use in  targeting  of 
drugs to colon. Certain plant polysaccharides such as amylose, inulin, 
pectin  and  guar  gum  remains  unaffected  in  the  presence  of 
gastrointestinal enzymes and pave the way for the formulation of colon 
targeted drug delivery systems. The concept of using pH as a trigger to 
release a drug in the colon is based on the pH conditions that vary 
continuously  down  the  gastrointestinal  tract.  Times  dependent  drug 
delivery systems have been developed that are based on the principle 
to prevent release of drug until 3-4 h after leaving the stomach. Redox 
sensitive polymers and bioadhesive systems have also been exploited 
to deliver the drugs into the colon.
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REVIEW OF LITERATURE
Hang  Lin  et  al., (2008) prepared  of  5-Fluorouracil  loaded 
polylactide-co-glycolide-co-methoxy  poly  (ethylene  glycol)  (PLGA-
mPEG)  nanoparticles  via  high  speed  shearing  5-Fluorouracil  (5-Fu) 
loaded nanoparticles (NPs) were prepared by a high speed shearing 
double emulsion method with polylactide-co-glycolide-co-methoxy poly 
(ethylene glycol) (PLGA-mPEG) as loading material. The prepared NPs 
possess a negative zeta potential and their loading efficiency is about 
15%  (mass  fraction).  The  result  of  in  vitro  release  shows  that  the 
release behavior of 5-Fu from NP's is coincident with zero-level release 
from the second day.
Rakesh  Patel,  (2008)  reviewed  nanotechnology  is  the  synergy  of 
mechanical,  material  sciences,  microelectronics,  electrical,  chemical  and biological 
screening.  Nanotechnologies  are  the  design,  characterization,  production  and 
application  of  structures,  devices  and  systems  by  controlling  shape  and  size  at 
nanometer  scale.  This  systemic  review  highlights  classifications,  preparation 
techniques,  characterization methods,  applications,  health implications and clinical 
aspects of nanoparticles. 
Ravi et al., (2008) developed a novel colon targeted tablet formulation using 
pectin as carrier and diltiazem HCl and indomethacin as model drugs. The tablets 
were coated with inulin followed by shellac and were evaluated for average weight,  
hardness  and  coat  thickness.  In  vitro release  studies  for  prepared  tablets  were 
carried out for 2 h in pH 1.2 HCl buffer, 3 h in pH 7.4 phosphate buffer and 6 h in  
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simulated colonic fluid.  The drug release from the coated systems was monitored 
using UV/V is spectroscopy.  In vitro studies revealed that  the tablets coated with 
inulin  and  shellac  have  limited  the  drug  release  in  stomach  and  small  intestinal 
environment and released maximum amount of drug in the colonic environment. The 
study revealed that polysaccharides as carriers and inulin and shellac as a coating 
material  can  be  used  effectively  for  colon  targeting  of  both  water  soluble  and 
insoluble drugs.
Su Li et al., (2008) studied the pharmacokinetic characteristics 
and  anticancer  effects  of  5-Fluorouracil  loaded  nanoparticles.  It  is 
expected that, prolonged circulation of anticancer drugs will  increase 
their anticancer activity while decreasing their toxic side effects. The 
purpose of this study was to prepare 5-fluorouracil (5-Fu) loaded block 
copolymers,  with  poly(γ-benzyl-L-glutamate)  (PBLG)  as  the 
hydrophobic block and poly(ethylene glycol) (PEG) as the hydrophilic 
block,  and  then  examine  the  5-Fu  release  characteristics, 
pharmacokinetics, and anticancer effects of this novel compound 5-Fu 
loaded PEG-PBLG (5-Fu/PEG-PBLG) nanoparticles were prepared by 
dialysis  and  then  scanning  electron  microscopy  (SEM)  and 
transmission  electron  microscopy  (TEM)  were  used  to  observe  the 
shape and size of the nanoparticles, and ultraviolet spectrophotometry 
was  used to  evaluate  the  5-Fu  in  vitro  release characteristics.  The 
pharmacokinetic parameters of 5-Fu/PEG-PBLG nanoparticles in rabbit 
plasma were determined by measuring the 5-Fu by high-performance 
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liquid  chromatography (HPLC).  To  study  in  vivo  effects,  LoVo cells 
(human colon cancer cell line) or Tca8113 cells (human oral squamous 
cell carcinoma cell line) were implanted in BALB/c nude mice that were 
subsequently  treated with  5-Fu or  5-Fu/PEG-PBLG nanospheres.  In 
this  model  system,  5-Fu/PEG-PBLG  nanoparticles  changed  the 
pharmacokinetic  behavior  of  5-Fu,  thus  increasing  its  anticancer 
activity. 5-Fluorouracil loaded nanoparticles have potential as a novel 
anticancer drug that may have useful clinical applications.
Xueming Li  et al., (2008)  investigated PLGA nanoparticles for 
the oral delivery of 5-Fluorouracil using high pressure homogenization-
emulsification  as  the  preparation  method  and  in  vitro/in  vivo  to 
incorporate the hydrophilic anti-cancer drug 5-Fluorouracil (5-Fu) into 
poly(lactide-co-glycolide)  (PLGA)  nanoparticles  (NP)  to  improve  the 
oral bioavailability. Owing to the high solubility of 5-Fu in basic water, 
the  water-in-oil-in-water  (w/o/w)  emulsification  process  has  been 
chosen as one of the most appropriate method for the encapsulation of 
5-Fu, and the ammonia solution was used as the inner aqueous phase 
solvent to increase the solubility of 5-Fu. In order to reach submicron 
size as well  as increasing the grade of monodispersity compared to 
previous preparation techniques, prepared 5-Fu loaded PLGA-NP by a 
high-pressure emulsification-solvent evaporation process. The PLGA-
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NPs were characterized with respect to their morphology, particle size, 
size  distribution,  5-Fu  encapsulation  efficiency,  in  vitro  and  in  vivo 
studies in rats. In vitro release of 5-Fu from nanoparticles appeared to 
have two components with an initial rapid release due to the surface 
associated drug and followed by a slower exponential release of 5-Fu, 
which was dissolved in the core. The in vivo  research was studied in 
male Sprague-Dawley rats after an oral 5-Fu dose of 45 mg/kg. Single 
oral  administration  of  5-Fu  loaded  PLGA-NP  to  rats  produced 
bioavailability,  which  was  statistically  higher  than  5-Fu  solution  as 
negative control and the MRT (mean residence time) of 5-Fu loaded 
PLGA-NP was significantly (p < 0.05) modified. Thus, it is possible to 
design  a  controlled  drug  delivery  system  for  oral  5-Fu  delivery, 
improving  therapy  efficiency  by  possible  reduction  of  time  intervals 
between peroral administrations and reduction of local gastrointestinal 
side effects.
Harikrishna  Devalapally  et  al., (2007)  reviewed  the  role  of 
nanotechnology in pharmaceutical product development. Nanoparticle 
technology  initially  arose  to  address  solubility  and  permeability 
problems  in  drug  development.  Advances  in  the  area  of 
nanoparticulate  drug  delivery  systems  have  allowed  some  of  the 
molecules  in  the  market  to  achieve  desirable  pharmacokinetic 
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properties  and  reducing  the  unwanted  toxicity,  improving  patient 
compliance, and clinical outcomes. In the development of NMEs can 
be  achieved  by  using  specific  types  of  nanosystems  in  the 
preformulation development  to  obtain  a balance between chemistry, 
pharmacology, and pharmacokinetics of drug.
Shinji  Sakuma et al., (2006)  reviewed the development of  a 
dosage form that improves the absorption of peptide and protein drugs 
via the gastrointestinal tract are one of the greatest challenges in the 
pharmaceutical field. Many researchers have taken up the challenge, 
using  approaches  including  mucoadhesive  drug  delivery,  colon 
delivery,  particulate  drug  delivery  such  as  nanoparticles, 
microcapsules,  liposomes,  emulsions,  micelles,  and  so  on.  The 
objective of this article is to provide the reader with outlines of novel 
nanoparticle technologies for oral peptide delivery based on polymer 
chemistry.  The physicochemical properties of nanoparticles and their 
behavior on exposure to physiological media are greatly dominated by 
their chemical structures and surface characteristics.
Fu-de Cui  et al., (2006)  investigated the preparation of PLGA 
nanoparticles  (PNP)  and  PLGA-Hp55  nanoparticles  (PHNP)  as 
potential drug carriers for oral insulin delivery. The nanoparticles were 
prepared by a modified emulsion solvent diffusion method in water, and 
38
their  physicochemical  characteristics,  drug  release  in  vitro  and 
hypoglycemic effects in diabetic rats were evaluated. The particle sizes 
of the PNP and PHNP were 150 ± 17 and 169 ± 16 nm, respectively,  
and the drug recoveries of  the nanoparticles were  50.30 ± 3.1 and 
65.41  ±  2.3%,  respectively.  The  initial  release  of  insulin  from  the 
nanoparticles in simulated gastric fluid over 1 h was 50.46 ± 6.31 and 
19.77 ± 3.15%, respectively.  The relative bioavailability of  PNP and 
PHNP compared with subcutaneous (s.c.) injection (1 IU/kg) in diabetic 
rats  was  3.68  ±  0.29  and  6.27  ±  0.42%,  respectively.  The  result 
revealed that, the use of insulin-loaded PHNP was an effective method 
of reducing serum glucose levels.
Paula  De  Angelis et  al., (2006)  cellular  response  to  
5-Fluorouracil  (5-Fu)  in  5-Fu-resistant  colon  cancer  cell  lines  during 
treatment and recovery gene expression data suggested that, altered 
regulation  of  nucleotide  metabolism,  amino  acid  metabolism, 
cytoskeleton  organization,  transport,  and  oxygen  metabolism  may 
underlie the differential resistance to 5-Fu seen in these cell lines.
Tuleu et al., (2006) investigated seven healthy male volunteers received on 
three  separate  occasions,  an  uncoated  or  amylose-ethylcellulose-coated 
hydroxypropylmethylcellulose capsule containing 4-aminosalicylic acid Na (550 mg), 
or  an  intravenous injection  of  
4-aminosalicylic  acid  Na (135 mg).  The capsules were radiolabelled with  99mTc to 
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allow  their  positions  in  the  gastrointestinal  tract  to  be  followed  using  a  gamma 
camera. Plasma and urine samples were collected and assayed for 4-Aminosalicylic 
acid and metabolite concentrations. The uncoated capsules broke down within 10 min 
in  the  stomach,  allowing  rapid  and  complete  absorption  of  the  drug.  The coated 
capsules remained intact in the upper gastrointestinal tract, and had a median gastric 
emptying  time  of  61  min  (interquartile  range,  
77 min) and a median colon arrival time of 363 min (interquartile range, 185 min). For 
the coated capsules, only the metabolite was detected in the plasma and/or urine 
after the capsules had reached the colon. The specific coating protected the drug 
until the capsule reached the colon, where 4-Aminosalicylic acid was slowly released 
and absorbed. Thus, such a formulation has the potential for use in the treatment of  
inflammatory bowel disease.
Ziyaur  Rahman  et  al., (2006)  prepared  and  evaluated  the  colon-specific 
microspheres of 5-Fluorouracil for the treatment of colon cancer. Core microspheres 
of alginate were prepared by the modified emulsification method in liquid paraffin and 
by  cross-linking  with  calcium  chloride.  The  core  microspheres  were  coated  with 
Eudragit S-100 by the solvent evaporation technique to prevent drug release in the 
stomach and small intestine. The microspheres were characterized by shape, size, 
surface  morphology,  size  distribution,  incorporation  efficiency,  and  in  vitro drug 
release studies. The outer surfaces of the core and coated microspheres, which were 
spherical  in  shape,  were  rough  and  smooth,  respectively.  The  size  of  the  core 
microspheres ranged from 22 to 55 µm, and the size of the coated microspheres 
ranged from 103 to 185 µm. The core microspheres sustained the drug release for 10 
hours.  The  release  studies  of  coated  microspheres  were  performed  in  a  pH 
progression medium mimicking the conditions of the gastrointestinal tract. Release 
was sustained for up to 20 hours in formulations with core microspheres to a Eudragit  
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S-100 coat ratio of 1:7, and there were no changes in the size, shape, drug content, 
differential scanning calorimetry thermogram, and in vitro drug release after storage 
at 40°C/75% relative humidity for 6 months.
Krishna  et al., (2005)  reviewed that nanoparticles are one of 
the novel colloidal drug delivery systems that hold great promise for 
reaching the goal  of  controlled drug delivery as well  as site-specific 
delivery. The present review highlights that several carriers used in the 
preparation  of  NPs  method  of  preparation.  Various  pharmaceutical 
considerations involved interaction of NPs with blood components and 
cell membranes, the physiochemical characterization of NPs and their 
therapeutic applications in the field of medicine. Nanoparticles are used 
for parentral, oral, ocular and transdermal applications as well as used 
in  cosmetics  and  hair  care  technologies,  sustained  release 
formulations and as a carrier for radio nucleotides in nuclear medicine.
Asuman  Bozkir  et  al., (2005) prepared  and  evaluated  an  orthogonal 
experimental  design  to  optimize  the  formulation  of  
5-Fluorouracil (5-Fu) loaded poly (D-L-Lactide-co-glycolide) (PLGA) nanoparticles (5-
Fu-NP)  by  a  nanoprecipitation-solvent  displacement  technique.  The  type  of 
surfactant, amount of acetone and molecular weight of the polymer with three levels 
of each factor were selected and arranged in an L18(35) orthogonal experimental table. 
From  the  statistical  analysis  of  the  data,  polynomial  equations  were  generated. 
Optimized formulations have the particle size ranging from 160 to 250 nm. Smallest 
nanoparticles (161 ± 1.22 nm) were obtained using Resomer PLGA 755 and pluronic 
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F-68  with  10  ml  acetone  amount.  Under  these  conditions  the  5-Fu  entrapment 
percentage  was  maximum  78.30%,  suggesting  5-Fu  might  be  entrapped  and 
adsorbed  on  the  nanoparticle  surface.  In  vitro  release  of  three  formulations  with 
maximum  drug  entrapment  efficiency  and  minimum  particle  size,  were  also 
investigated by release kinetics.  According to  the determined coefficients,  release 
data fit to Higuchi's diffusion kinetics. The  in vitro  release of 5-Fu-NP in phosphate 
buffered saline (PBS,  pH 7.4)  is  suggested to  be controlled by a  combination of  
diffusion with slow and gradual erosion of the particles. Also, the antimicrobial activity 
was observed even on the end of seventh day with all formulations.
Ugo  Bilati  et  al., (2005)  investigated  the  entrapment  of  
3 different model proteins (tetanus toxoid, lysozyme, and insulin) into 
poly (D,L-lactic acid) and poly(D,L-lactic-co-glycolic acid) nanoparticles 
and to  address process-related  stability  issues.  For  that  purpose,  a 
modified  nanoprecipitation  method  as  well  as  2  emulsion-based 
encapsulation  techniques  (i.e.,  a  solid-in  oil-in  water  (s/o/w)  and  a 
double emulsion (w1/o/w2) method) were used. The main modification 
of  nanoprecipitation  involved  the  use  of  a  wide  range  of  miscible 
organic solvents such as dimethylsulfoxide and ethanol instead of the 
common acetone and water. The results obtained showed that tetanus 
toxoid  and  lysozyme  were  efficiently  incorporated  by  the  double 
emulsion procedure when ethyl  acetate was used as solvent (>80% 
entrapment  efficiency),  The  nanoprecipitation  method  led  to  a 
homogenous population of small nanoparticles (with size ranging from 
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~130 to 560 nm) and in some cases also improved experimental drug 
loadings, especially for lysozyme (entrapment efficiency >90%). With 
respect to protein stability, the duration and intensity of sonication were 
not a concern for tetanus toxoid, which retained more than 95% of its 
antigenicity  after  treatment  for  1  minute.  Only  a  high  methylene 
chloride:water ratio was shown to slightly decrease toxoid antigenicity.  
Finally, no more than 3.3% of A21 desamido insulin and only traces of  
covalent insulin dimer were detected in nanoparticles. In conclusion, 
both  the  double  emulsion  and  nanoprecipitation  methods  allowed 
efficient protein encapsulation. MALDI-TOF MS allowed accurate drug 
content determination. The manufacturing processes evaluated did not 
damage the primary structure of insulin.
Peter Watts et al.,  (2005) designed a technology for site-specific delivery of 
drugs in the gastrointestinal  (GI)  tract  and,  in particular,  targeted release into the 
colonic region. A key area of application is the delivery of therapeutic agents for local  
treatment of lower GI diseases. The technology is based on the application of pH-
sensitive  coatings  onto  injection-moulded  starch  capsules.  An  extensive  body  of 
clinical  data  has  been  generated  showing  reliable  
in vivo performance of the capsules. In γ-scintigraphy studies around 90% of TARGIT 
capsules (n=84) delivered their contents to the target site of the terminal ileum and 
colon. TARGIT-based products are in active clinical development for the treatment of 
conditions including inflammatory bowel diseases.
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Shantha  et al., (2005)  reviewed colon-targeted delivery  of  bioactives  has 
recently  gained  importance  in  addressing  specific  needs in  the  therapy  of  colon-
based diseases.  Many approaches have  been  attempted  for  the  development  of  
colon-specific delivery systems, with not much success in the past. Recent research 
into the utilization of the metabolic activity and the colonic microenvironment in the 
lower  gastrointestinal  tract  has attained great  value in  the design  of  novel  colon-
targeted delivery systems based on natural biodegradable polymers. In the current 
article, special emphasis has been placed on polysaccharide systems, with minimal 
chemical  modification,  that  have  been  exploited  for  colon  targeting.  These 
polysaccharide based encapsulation and targeted delivery systems are envisaged to 
have an immense potential for the development of food/nutraceutical formulations for 
colon-based diseases, including colorectal cancer.
Ugo Bilati  et al., (2004) investigated formulation and process modifications 
to improve the versatility of the nanoprecipitation technique, particularly with respect 
to  the  encapsulation  of  hydrophilic  drugs  (e.g.  proteins).  More  specifically,  the 
principal objective was to explore the influence of such modifications on nanoparticle 
size. Selected parameters of the nanoprecipitation method, such as the solvent and 
the  non-solvent  nature,  the  solvent/non-solvent  volume  ratio  and  the  polymer 
concentration, were varied so as to obtain polymeric nano-carriers. The feasibility of 
such a modified method was assessed and resulting unloaded nanoparticles were 
characterized  with  respect  to  their  size  and  shape.  It  was  shown  that  the  mean 
particle  size  was  closely  dependent  on  the  type  of  non-solvent  selected.  When 
alcohols  were  used,  the  final  mean size  increased  in  the  sequence:  methanol  < 
ethanol  <  propanol.  Surfactants  added  to  the  dispersing  medium  were  usually 
unnecessary  for  final  suspension  stabilization.  Changing  the  solvent/non-solvent 
volume ratio was also not a determinant factor for nanoparticle formation and their 
44
final characteristics, provided that the final mixture itself did not become a solvent for 
the polymer. A too high polymer concentration in the solvent, however,  prevented 
nanoparticle formation. Both poly (lactic acid) (PLA) and poly (D-L-lactic-co-glycolic 
acid) (PLGA) could be used by accurately choosing the polymer solvent and in this 
respect,  some non-toxic  solvents with  different  dielectric  constants  were selected. 
The nanoparticles obtained ranged from about 85–560 nm in size. The nanoparticle 
recovery step however needs further improvements, since bridges between particles 
which  cause  flocculation  could  be  observed.  The  results  revealed  that  the 
nanoprecipitation technique is more versatile and flexible than previously thought and 
that a wide range of parameters can be modified.
Krishnaiah et al., (2002) conducted in vivo evaluation of orally administered 
guar  gum-based  colon-targeted  tablet  formulations  of  celecoxib  (colon-targeted 
tablet-20 or colon-targeted tablet-30) as compared with an immediate release capsule 
in 15 human volunteers. Blood samples were obtained at different time intervals and 
the plasma concentration of celecoxib was estimated by reversed phase HPLC. The 
immediate release capsules of celecoxib might have disintegrated very fast in GI tract 
and  absorbed  quickly  from stomach  and  small  intestine  thereby  producing  peak 
plasma  concentration  (Cmax of  
478±57 ng/ml) within 3.8±0.1 h (Tmax).  Though celecoxib could be seen in plasma 
after  oral  administration  of  colon-targeted  tablet-20  or  colon-targeted  tablet-30 
between 1 and 2 h, low levels of drug were observed up to 8 h resulting in peak 
concentration  (Cmax)  of  78±6  ng/ml  or  
88±15 ng/ml at 10.5±1.9 h or 13.5±1.4 h (Tmax) respectively, whereas the immediate 
release  capsules  produced peak plasma concentration  (Cmax)  of  478±57 ng/ml  at 
3.8±0.1  h  (Tmax).  Colon-targeted  tablets  showed  decreased  AUC0-∞,  Cmax  and 
absorption  rate  constant,  prolonged  absorption  time  (ta)  and  increased  t1/2 in 
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comparison with the immediate release capsules. The results of the study indicated 
that the guar gum-based colon-targeted tablets of celecoxib did not release the drug 
significantly in stomach and small intestine, but delivered to the colon resulting in a 
slow absorption of the drug and making it available for local action in the colon.
Sinha et al.,  (2001) reviewed polysaccharides in colon-specific 
drug delivery. Natural polysaccharides are now extensively used for the 
development of solid dosage forms for delivery of drug to the colon. 
The rationale for the development of a polysaccharide based delivery 
system  for  colon  is  the  presence  of  large  amounts  of 
polysaccharidases in the human colon as the colon is inhabited by a 
large number and variety  of  bacteria  which secrete many enzymes. 
E.g.  D-galctosidase,  amylase,  pectinase,  xylanase,  dextranase  etc. 
Various major approaches utilizing polysaccharides for colon-specific 
delivery are fermenting coating of the drug core, embedding of the drug 
biodegradable  matrix  and  formulation  of  drug-saccharide  conjugate 
(prodrugs).  A  large  number  of  polysaccharides  have  already  been 
studied for their potential as colon-specific drug carrier systems, such 
as  chitosan,  pectin,  guar  gum,  inulin  etc.  Recent  efforts  and 
approaches  exploiting  these  polysaccharides  in  colon-specific  drug 
delivery are discussed.
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Miller  et al., (2001)  reviewed that the major problem of many 
newly developed pharmaceutical drugs is their poor solubility in water 
and  simultaneously  in  organic  media.  To  solve  these  problems 
formulation as nanosuspensions is an attractive alternative. During, the 
drug  development  process  screening  for  an  optimal  formulation  by 
homogenization is essential. Time and cost effective production in an 
initial phase of R&D can be conducted on lab scale by using the Micron 
Lab  40  in  its  discontinuous  version.  Reproducibility  of  small  scale 
production  parameters  (particle  size,  size  distribution,  content  of 
microparticles) was exemplary studied for the drug RMKP22.
Wen  Juan  Jia  et  al., (2000)  a  biodegradable  polyetherester 
copolymer  (PCL/PEG/PCL,  PCEC)  as  synthesized  by  ring-opening 
polymerization of caprolactone initiated by poly(ethylene glycol) (PEG). 
The PCEC nanoparticles were prepared by solvent diffusion method or 
w/o/w  double  emulsion  method.  The  obtained  particles'  morphology 
was observed on scanning electron microscopy, and the particle size 
distribution was determined using Malvern laser particle sizer. Bovine 
serum  albumin  was  used  as  the  model  water-soluble  protein  drug, 
which was successfully encapsulated in PCEC nanoparticles; the drug 
release  behavior  was  studied  in  detail.  The  hydrolytic  degradation 
behavior of the PCEC nanoparticles was also studied.
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Sarasija et al., (1999) reviewed that the colon specific delivery 
of drugs are of interest for the treatment of colonic diseases, so as to 
maximize the effectiveness of these drugs. Oral delivery of peptides 
and  proteins  are  possible  because  colon  provides  a  more  friendly 
environment than the upper gastrointestinal tract. Colon is also rich in 
lymphoid tissue so uptake of antigens into the mast cells of the colonic 
mucosa produces rapid local production of antibodies thus helping in 
vaccine delivery. This review dealt with the anatomy and physiology of 
colon and various aspects of formulations by which colon targeting of 
drugs can be achieved.
Thirumala  Govender  et  al., (1999)  investigated  the 
nanoprecipitation technique for preparation of nanoparticles suffers the 
drawback of poor incorporation of water soluble drugs. The aim of this 
study  was  therefore  to  assess  various  formulation  parameters  to 
enhance  the  incorporation  of  a  water  soluble  drug  (procaine 
hydrochloride)  into  poly  (D-L-Lactide-co-glycolide)  (PLGA) 
nanoparticles prepared by this technique. Approaches investigated for 
drug incorporation  efficiency enhancement  included  the  influence  of 
aqueous  phase  pH,  replacement  of  procaine  hydrochloride  with 
procaine dihydrate and the inclusion of excipients:  poly (D-L-lactide) 
(PLA)  oligomers,  poly  (methyl  methacrylate-co-methacrylic  acid) 
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(PMMA–MA)  or  fatty  acids  into  the  formulation.  The  nanoparticles 
produced were submicron size (<210 nm) and of low polydispersity. It 
was found that an aqueous phase pH of 9.3, replacement of procaine 
hydrochloride with procaine dihydrate and the incorporation of PMMA–
MA, lauric and caprylic acid into the formulation could enhance drug 
incorporation efficiency without the size, morphology and nanoparticle 
recovery  being  adversely  influenced.  For  instance  changing  the 
aqueous phase pH from 5.8  to  9.3  increased nanoparticle  recovery 
from 65.1  to  93.4%,  drug  content  from  0.3  to  1.3% w/w  and  drug 
entrapment from 11 to 58.2%. However, the presence of high ratios of 
lauric acid and procaine dihydrate in the formulation adversely affected 
the  morphology and size  of  the  nanoparticles.  Also,  PLA oligomers 
were  not  considered  a  feasible  approach  since  it  decreased  drug 
entrapment from 11 to 8.4% and nanoparticle recovery from 65.1 to 
19.6%.  Drug  release  from  nanoparticles  appears  to  consist  of  two 
components  with  an  initial  rapid  release  followed  by  a  slower 
exponential  stage.  This  study  has  demonstrated  that  formulation 
variables can be exploited in order to enhance the incorporation of a 
water soluble drug into PLGA nanoparticles by the nanoprecipitation 
technique.
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David  Quintanar-Guerrero  et  al., (1998) reviewed  the 
techniques  available  to  prepare  biodegradable  nanoparticles  from 
preformed polymers. Although there is abundant literature on this topic, 
only a few focuses on the thorough analysis of preparative procedures, 
In  particular,  four  techniques  are  discussed  in  terms  of  their 
technological advantages and drawbacks: emulsification, evaporation, 
solvent  displacement,  salting  out  and  emulsification  diffusion.  The 
proposed mechanism of nanoparticle formation for each technique is 
described  from  a  physicochemical  perspective.  The  effects  of 
preparative  variables  on  nanoparticle  size  and  drug-entrapment 
efficiency are also discussed.
Shoba  Rani  et  al., (1998)  reviewed  the  importance 
nanoparticles  as  drug  delivery  systems.  Nanoparticles,  one  of  the 
colloidal  drug delivery systems,  hold great  promise for  reaching the 
goal of controlled drug delivery as well as site specific delivery.  This 
review  presents  various  methods  of  preparation,  characterization, 
stability, drug release and applications of nanoparticles. If appropriately 
investigated,  nanoparticles may open new avenues in  research and 
therapy.
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Wilding  et al., (1998) investigated the scintigraphic evaluation 
of a new capsule-type colon specific drug delivery system in healthy 
volunteers  to  provide  “proof  of  concept”  for  a  novel  capsule-type 
colonic delivery system (colon targeted delivery capsule). The lack of 
predictive in vitro or animal model leads to considerable time delays in 
colonic  product  development  .The human data  validates  the  design 
concept behind the release mechanism, in that capsule disintegration, 
and hence drug release, did not start until 5 h after gastric emptying 
irrespective of whether the product was administered to fasted or fed 
subjects.  However,  the  potential  for  prolonged gastric  residence  for 
large enteric coated products intended for intestinal targeting was also 
observed. Overall, the study provides a focus for subsequent product 
development  and  highlights  the  role  of  scinitigraphy  in  dynamically 
visualizing the drug delivery process.
Takashi Ishibashi  et al., (1998)  investigated a new capsule-type dosage 
form for colon-targeted delivery of drugs. The system was designed by imparting a 
timed-release  function  and  a  pH-sensing  function  to  a  hard  gelatin  capsule.  The 
technical characteristics of the system are to contain an organic acid together with an 
active ingredient in a capsule coated with a three-layered film consisting of an acid-
soluble polymer, a water-soluble polymer, and an enteric polymer. In order to find the 
suitable formulation, various formulation factors were investigated through a series of 
in vitro dissolution studies. As a result, it was found that: (1) various organic acids can 
be used for this system; (2) a predictable timed-release mechanism of a drug can be 
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attained by adjusting the thickness of the Eudragit E layer; and (3) the outer enteric 
coating  with  HPMC-AS  provided  acceptable  acid-resistibility.  All  these  results 
suggested that this approach can provide a useful and practical means for colon-
targeted delivery of drugs.
Van  Den  Mooter  et  al., (1995)  evaluated  azo  polymers  based  upon  2-
hydroxyethyl methacrylate, methyl methacrylate, and methacrylic acid, and containing 
N,N'-bis  [(methacryloyloxyethyl)  oxy(carbonylamino)]azobenzene  as  azo  aromatic 
agent  in  vivo  as  coatings  for  colon-specific  drug  delivery.  The  gastrointestinal 
absorption of theophylline from capsules coated with the azo polymers was examined 
in the proximal part of the small intestine and the caecum of male Wistar rats. The 
capsules were surgically inserted in the region of interest. The plasma concentration 
of the drug was higher when the capsules were inserted in the caecum as compared 
to the small intestine. The appearance of theophylline in the plasma when capsules 
were administered in the small intestine can be attributed to simple diffusion of the 
drug through the swollen polymer coating. Release and absorption from the caecum 
is the combined result of diffusion and degradation of the azo polymer coatings by 
bacterial azo reductase.
Proano et al., (1990) used a noninvasive method to label the solid phase of 
contents in the unprepared human colon. 111In-labeled Amberlite pellets (0.5-1.8 mm 
dia) were  placed  in  a  gelatin  capsule  that  was  then  coated  with  a  pH-sensitive 
polymer (methacrylate).  In vitro, the capsules disintegrated in simulated small bowel 
contents  within  
1-2 h; when ingested by healthy subjects,  capsules released radiolabel in the distal 
ileum or  proximal  colon in 13 of 15 subjects.  Transit  of  111In-pellets  through the 
unprepared colon could then be quantitated radioscintigraphically. Segmental transit 
was  defined in  the  ascending  (AC),  transverse  (TC),  descending  (DC),  and 
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rectosigmoid (RS)  colon.  Radioactivity  was  also  quantitated  in  stools.  At  12  h, 
radioactivity was most obvious in the AC (59 +/- 11%, mean +/- SE) and the  TC (21 
+/-  6%);  at  24 h,  counts were distributed equally  between AC, TC,  and stools (P 
greater than 0.05); by 48 h, 56 +/- 11% counts had been  excreted, although 30 +/- 
10% remained in the TC. At 24 and 48 h, the amount in DC or RS was lower (p < 
0.05) than in the TC or in stools. Emptying of the AC was characterized by an initial 
lag period, when no counts emptied into the TC, followed by a period of emptying that 
was approximately linear. Thus this simple approach is able to label contents in the 
healthy human colon.  The ascending  and  transverse  colon  appear to  be  sites of 
storage of solid residue, whereas the left colon and rectosigmoid  function mainly as 
conduits.
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DRUG PROFILE
STRUCTURE  OF  5-FLUOROURACIL
Category : A pyramidine antagonist, is an 
antimetabolite
Antineoplastic agent
Chemical name : 2, 4(1H, 3H)-pyrimidinedione
Synonyms : 2, 4-Dihydroxy-5-
fluropyrimidine 5-Fu;
5-Fluracil
Molecular weight : 130.08
Molecular formula : C4H3FN2O2
Appearance : Solid
Color : White
Freezing / melting point : 280-282° C
Decomposition temperature : 80° C
O
F
N
H
O
N
H
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Solubility : Sparingly soluble in water; 
slightly soluble in ethanol 
(95%); practically insoluble in 
chloroform and in ether
Conditions to avoid : Light
Chemical stability : Stable under normal 
temperatures and pressure.
Trade names : NSC-19-893; Ro-Efudex; 
Fluroplex; fluorouracil
Absorption spectroscopy
The UV absorption spectrum shows a maximum at 265-266 nm 
(epsilon=7.070)  and  a  minimum  at  232  nm  (in  acetate  buffer,  pH 
4.7).This,  as  well  as  IR,  NMR  (proton  and  19  F),  and  florescence 
spectral data (λmax exc =315, λmax em =391)
Adverse effects
• CNS: Lethargy, malaise, weakness, euphoria, acute cerebellar 
syndrome,  photophobia,  lacrimation,  decreased  vision, 
nystagmus, diplopia
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• GI:  Diarrhea,  anorexia,  nausea,  vomiting,  cramps,  enteritis, 
duodenal  ulcer,  duodenitis,  gastritis,  glossitis,  stomatitis, 
pharyngitis, esophagopharyngitis
• CV: Myocardial ischemia, angina
• Hematologic:  Leukopenia,  thrombocytopenia,  elevations  in 
alkaline  phosphatase,  serum  transaminase,  serum  bilirubin, 
lactic dehydrogenase
• Dermatologic:  Alopecia,  dermatitis,  maculopapular  rash, 
photosensitivity,  nail  changes  including  nail  loss,  dry  skin, 
fissures
• Other: Fever, Epistaxis
5-Fluorouracil (5-Fu), a pyrimidine analog, has a stable fluorine 
atom in place of a hydrogen atom at position 5 of the uracil ring. The 
fluorine  interferes  with  the  conversion  of  deoxyuridylic  acid,  thus 
depriving the cell of one of the essential precursors for DNA synthesis. 
5-Fu  is  employed  primarily  in  the  treatment  of  solid  growing  solid 
tumors (for example, colorectal, breast, ovarian, pancreatic, and gastric 
carcinomas).  Adjuvant  therapy  with  levamisole  -  a  veterinary 
anthelmintic agent - improves the survival of some patients with colon 
cancer. When applied topically, 5-Fu is also effective for the treatment 
of superficial basal cell carcinomas.
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1. Mechanism of action: 5-Fu has a good antineoplastic activity. It 
enters the cell through a carrier - mediated transport system and 
is converted to the corresponding deoxynucleotide (5-FdUMP), 
which  competes  with  deoxyuridine  monophosphate  for 
thymidylate synthase. 5FdUMP acts as apseusubstrate and is 
trapped  with  the  enzyme  and  its  N5,  N10–methylene 
tetrahydrofolic acid (leucovorin) coenzyme in a ternary complex 
that cannot proceed to products. DNA synthesis decreases due 
to lack of thymidine, leading to imbalanced cell growth and cell 
death. 5-Fu is also incorporated into RNA, and low levels have 
been detected in DNA. In the later case, a glycosylase excises 
the 5-Fu damaging the DNA.
2. Pharmacokinetics:  .Because  of  its  severe  toxicity  to  the  GI 
tract, 5-Fu is given in the case of skin cancer, topically. The drug 
penetrates  well  into  all  tissues,  including  the  CNS.  5-Fu  is 
rapidly metabolized in the liver, lung and kidney; it is eventually 
converted to CO2, which is exhaled. The dose of 5-Fu must be 
adjusted in the case of hepatic function.(Tripathi et al., 2008 and 
Mary J.Mycek et al., 1997)
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POLYMER PROFILE
1. POLY (D, L-LACTIDE-CO-GLYCOLIDE) PLGA
Structure
PLGA is a copolymer which is used in a host of Food and Drug 
Administration (FDA)  approved  therapeutic  devices,  owing  to  its 
biodegradability and biocompatibility. PLGA is synthesized by means of 
random ring-opening co-polymerization of two different monomers, the 
cyclic dimers (1,4-dioxane-2,5-diones) of glycolic acid and lactic acid.
Depending  on  the  ratio  of  lactide  to  glycolide  used  for  the 
polymerization,  different  forms of  PLGA can be obtained:  these are 
usually identified in  regard to  the monomers'  ratio used (e.g. PLGA 
75:25 identifies a copolymer whose composition is 75% lactic acid and 
25% glycolic acid. All PLGAs are amorphous rather than crystalline and 
show a glass transition temperature in the range of 40-60 °C.
PLGA can be dissolved by a wide range of common  solvents, 
including  chlorinated solvents,  tetrahydrofuran,  acetone or  ethyl  
acetate.
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PLGA  degrades  by  hydrolysis of  its  ester  linkages  in  the 
presence  of  water.  It  has  been  shown  that  the  time  required  for 
degradation  of  PLGA  is  related  to  the  monomers'  ratio  used  in 
production. The higher the content of glycolide units, the lower the time 
required for degradation. An exception to this rule is the copolymer with 
50:50 monomers' ratio which exhibits the faster degradation (about two 
months).
PLGA  has  been  successful  as  a  biodegradable  polymer 
because it  undergoes hydrolysis  in the body to produce the original 
monomers, lactic acid and glycolic acid. These two monomers under 
normal physiological conditions are by-products of various  metabolic 
pathways in the body.  Since the body effectively deals with the two 
monomers,  there  is  very  minimal  systemic  toxicity associated  with 
using  PLGA  for  drug  delivery  or  biomaterial  applications.
(www.wikipedia.com).
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2. EUDRAGIT RL 100
Commercial form
Eudragit RL 100/ RS 100
Structure
CHARACTERS
Description
Colour
Colurless, clear to  cloudy granules with a faint amine-like colour
Solubility
Soluble  in  ethanol,  isopropyl  alcohol,acetone  and  methylene 
chloride. Practically insoluble in petroleum ether,water.
Particle size
At least 90% < 0.315 mm.
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Film formation
When the test solution is poured onto a glass plate a clear film 
forms upon evaporation of the solvents
Dry substance / Residue on evaporation
Not less than 97.0%.1 gm of the substance is dried in an oven 
for 5 hours in vaccum at 80o C.
Loss on drying : Maximum 3%
Viscosity/ Apparent viscosity : Maximum 15mPa.s
Refractive index : nD20.1.380-1.385
Relative density : 0.816-0.836
Storage
Protect  from  warm  temperatures,Protect  from  moisture.
(www.wikipedia.com)
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3. POLOXAMER  188
Structure
Nonproprietary names
BP : Poloxamers
PhEur : Poloxamera
USPNF : Poloxamer
Synonyms
Lutrol, Monolan, Pluronic, Symperonic, Supronic and Poloxalkol
Chemical name and CAS registry number
α-Hydro-co-hydroxypoly  (oxyethylene)  poly  (oxypropylene)poly 
(oxy ethylene) block copolymer
HO(C2H4O)a(C3H6O)b(C2H4O)aH
CAS No. : 9003-11-6
Molecular weight : 7680-9510
Functional category
Dispersing agent; emulsifying agent; solubilizing agent; tablet 
lubricant; wetting agent.
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Description
Poloxamers generally occur as white, waxy, free flowing prilled 
granules, or as cast solids. They are practically odorless and tasteless. 
Density : 1.06 g/cm3 at 25o C
HLB Value : 29
Melting point : 52-57o C
Solubility : Freely soluble in ethanol and 
water
Surface tension : 19.8 mN/m (19.8 dynes/cm) 
for a 0.1%w/v aqueous 
Poloxamer solution at 25o C
Viscosity : 1000 mPas (1000 cP), melts 
at 77o C
Stability and storage conditions
Poloxamers are stable materials. Aqueous solutions are stable 
in the presence of acids, alkalis,  and metal  ions.  However  aqueous 
solutions support mould growth.
The bulk materials should be stored in a well-closed container in 
a cool, dry place.
Incompatibilities
Poloxamer 188 is incompatible with phenols and parabens.
63
Method of manufacture
Poloxamer polymers are prepared by reacting propylene oxide 
with propylene glycol to form polyoxypropylene glycol. Ethylene oxide 
is then added to form the block polymer.
Safety
Poloxamers are used in a variety of oral, parenteral and topical 
pharmaceutical  formulations and are generally regarded as nontoxic 
and non-irritant materials. Poloxamers are not metabolized in the body. 
(Raymond.C.Rower et al., 2003).
Applications of Poloxamer in pharmaceutical field
Use Concentration (%)
Wetting agent 0.01-5
Tablet excipients 5-10
Tablet coating 10
Stabilizing agent 1-5
Gelling agent 15-50
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MATERIALS AND METHODS
Materials used for the preparation and evaluation of 
5-Fluorouracil nanoparticles
Materials Grade Source
5-Fluorouracil Extra pure,
RM-1502
Himedia Laboratories Pvt. 
Ltd, Mumbai
Eudragit RL 100 Ozone International, Mumbai
Hydrochloric acid - Lobachemie Ltd, Mumbai
Methanol
-
Lobachemie Ltd, Mumbai
Potassium 
dihydrogen 
phosphate -
Himedia Laboratories Pvt. 
Ltd, Mumbai
Disodium hydrogen 
phosphate -
Lobachemie Ltd, Mumbai
Sodium hydroxide LR
Spectra reagent & 
Chemicals Pvt. Ltd
Distilled water Double 
distilled
Aqua Purification
Systems, Salem
Diethyl Phthalate -
Lobachemie Ltd, Mumbai
Acetone -
Lobachemie Ltd, Mumbai
Dichloromethane - Lobachemie Ltd, Mumbai
PLGA 50:50, 25:75
Sigma Aldrich,
Germany
Dibutyl phthalate -
Lobachemie Ltd, Mumbai
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EQUIPMENTS USED
Equipments used for the preparation of nanoparticles
Equipment Model/company
Freeze Drier Labconco,USA
Scanning Electron 
Microscope Jeol Jsm-6400
Dissolution test apparatus Digital dissolution test Apparatus, Lab India.
UV Visible 
spectrophotometer UV-1650 PC
FT/ IR Spectrometer FT IR--8400S(CE),SHIMADZU
IR-hydraulic Pellet Press M-15, KBr press,
Digital Balance H.R- 200, A&D – company Ltd.
Rotary Flask Evaporator Double Coiled Condenser, Superfit
pH Meter LI- 120, ELICO
Magnetic Stirrer Remi Equipments Ltd
Vaccum dessicator -
Vortex Mixer CM 101 Cyclo Mixer
Mechanical Stirrer RQ-122, Remi Equipments Ltd
Water Purifier Model No.2874/06, Tka Ltd
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ANALYTICAL METHODS
Preformulation studies
Infrared (IR) absorption spectroscopy
To investigate any possible interactions between the drug and the 
polymers,  the IR spectra of  pure 5-Fluorouracil,  PLGA and its  physical 
mixtures (1:1) with PLGA were carried out using Shimadzu FT IR 8400 S 
(CE) spectrophotometer (Tokyo, Japan). The samples were prepared as 
KBr pellets compressed under a pressure of 6 ton /nm2.  The wavelength 
selected  ranged  between  400  -  4000cm-1  in  a  Perkin  Elmer  FTIR 
spectrophotometer.  The  IR  spectrum  of  the  physical  mixture  was 
compared with those of pure drug and polymer,  matching was done to 
detect any appearance or disappearance of peaks.
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Fig. 3 IR SPECTRUM OF  5 -FLUOROURACIL
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Fig. 4  IR SPECTRUM OF  PLGA
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Fig. 5  IR SPECTRUM OF  OF  PHYSICAL MIXTURE  OF  5 -FU  +  PLGA  (1:1)
76
PREPARATION OF STANDARD GRAPH OF 5-FLUOROURACIL
USING   PHOSPHATE BUFFER pH 7.4
Accurately  weighed  quantity  of  100  mg  of  5-Fluorouracil  was 
transferred in to a 100 ml standard flask and volume is made up to the 
level of standard flask with phosphate buffer (pH.7.4). From the primary 
stock solution 2 ml was diluted to 100 ml with phosphate buffer (pH 7.4) in 
order  to  produce  a  concentration  of  20  µgm/ml  solution.  The  above 
working solution was subsequently diluted with respective buffer to obtain 
a series of dilutions of 2µgm/ml, 4µgm/ml, 6µgm/ml, 8µgm/ml, 10µgm/ml, 
12µgm/ml,  14µgm/ml,  16µgm/ml,  18µgm/ml  and  20µgm/ml.  The 
absorbance  of  the  above  solutions  was  measured  in  UV-visible 
spectrophotometer at 266 nm using their blank. 
PREPARATION OF STANDARD GRAPH OF 5-FLUOROURACIL
USING   PHOSPHATE BUFFER pH 6.8
Accurately  weighed  quantity  of  100  mg  of  5-Fluorouracil  was 
transferred in to a 100 ml standard flask and volume is made up to the 
level of standard flask with phosphate buffer (pH.6.8). From the primary 
stock solution 2 ml was diluted to 100 ml with phosphate buffer (pH 6.8) in 
order  to  produce  a  concentration  of  20  µgm/ml  solution.  The  above 
working solution was subsequently diluted with respective buffer to obtain 
a series of dilutions of 2µgm/ml, 4µgm/ml, 6µgm/ml, 8µgm/ml, 10µgm/ml, 
12µgm/ml,  14µgm/ml,  16µgm/ml,  18µgm/ml  and  20µgm/ml.  The 
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absorbance  of  the  above  solutions  were  measured  in  UV-visible 
spectrophotometer at 266nm using the blank.
PREPARATION OF STANDARD GRAPH OF 5-FLUOROURACIL
USING   PHOSPHATE BUFFER pH 1.2
Accurately  weighed  quantity  of  100  mg  of  5-Fluorouracil  was 
transferred in to a 100 ml standard flask and volume is made up to the 
mark  with  hydrochloric  acid  buffer  (pH-1.2).  From  the  primary  stock 
solution 10 ml was diluted to 100 ml with  hydrochloric acid (pH-1.2) in 
order  to  produce  a  concentration  of  100  µgm/ml  solution.  The  above 
working solution were subsequently diluted with respective buffer to obtain 
a series of dilutions of  10µgm/ml,  20µgm/ml,  30µgm/ml,  40µgm/ml  and 
50µgm/ml.  The absorbance of  the  above  solutions  were  measured in  
UV-visible spectrophotometer at 266nm using buffer as blank. 
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Table  1:    Standard graph of 5-Fluorouracil at pH 7.4
S. No Concentration (mcg/ml) Absorbance at 266 nm
1 2 0.11536 
2 4 0.20630 
3 6 0.29843 
4 8 0.39001 
5 10 0.51038 
6 12 0.59875 
7 14 0.70923 
8 16 0.77332 
9 18 0.91687 
10 20 0.99768 
Fig. 6  :    Standard graph of 5-Fluorouracil at pH 7.4
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 2 4 6 8 10 12 14 16 18 20
Concentration mcg/ml
A
bs
or
ba
nc
e
79
Table 2 : Standard graph of 5-Fluorouracil at pH 6.8
S. No Concentration (mcg/ml) Absorbance at 266 nm
1 2 0.12695 
2 4 0.2616 
3 6 0.37317 
4 8 0.50537 
5 10 0.61682 
Fig. 7 : Standard graph of 5-Fluorouracil at pH 6.8
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Table  3 :   Standard graph of 5-Fluorouracil at pH 1.2
S. NO Concentration (mcg/ml) Absorbance at 266 nm
1 10 0.15222
2 20 0.25825 
3 30 0.43005
4 40 0.56055 
5 50 0.68311
Fig. 8 :  Standard graph of 5-Fluorouracil at pH 1.2
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METHODOLOGY
Preparation of drug loaded nanoparticles
Drug loaded NP were prepared using a nanoprecipitation method. 
An accurately  weighed quantity of 100mg  PLGA was dissolved in 10 ml 
of acetone and accurately about 4.0 mg of 5-Fluorouracil was weighed and 
dissolved in the polymer solution was poured immediately into a stirred, 
aqueous solution of 0.5% (w/v) Poloxamer 188 previously filtered through 
0.22  mm  poly  (carbonate)  filter.  The  resulting  cloudy  suspension  was 
transferred expeditiously to a round –bottomed flask and evaporated under 
reduced pressure for 20 minutes at 40o.C. The product was then freeze 
dried. (McCarron et al., 2008). 
Table  4 : Preparation of 5-Fluorouracil Nanoparticles 
S. No Formulation code Drug Polymer
1 NP-1 5-Fu PLGA (50: 50)
2 NP-2 5-Fu PLGA (25:75)
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Fig. 9 : Preparation of Nanoparticles
SCANNING ELECTRON MICROSCOPE (SEM) OBSERVATION
The  morphology  of  obtained  particles  of  5-Fluorouracil 
nanoparticles  was  examined  by  scanning  electron  microscope  (SEM) 
JEOL  JSM-6400  at  30  KV  magnification  at  room  temperature.  Before 
scanning nanoparticle sample were sputtered  with platinum  (HITACHI, E-
1010, ION SPUTTER) (Fig.  10 and 10A),  shows  the magnification of 
sample at 2000 and 3000 .
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 Fig. 10:  X- 2000 Magnification
84
 Fig. 10A : X -3000 Magnification SEM Images
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DETERMINATION OF 5-FU CONTENTS OF NANOPARTICLES
Five  milliliters  of  methylene  chloride  was  added  to  30  mg  of 
lyophilized  5-FU-nanoparticles  (5Fu-NP)  for  digestion  and  10  ml  of  bi-
distilled water was added in order to extract the 5-Fu. The aqueous layer 
was filtered through a membrane filter and assayed spectrophotometrically 
at 266 nm. The entrapping efficiency (EE) of 5Fu- NP was calculated using 
the equation (Asuman   and Ongum, 2005).
EE (%) = [(a × b) ⁄ c] × 100 
NP - 1
a - Weight of nanoparticle;
b-Drug content;
c-  Added drug amount.
Weight of the nanoparticle  = 30mg
Drug content in the nanoparticle  = 0.02185mg
Added drug amount  = 0.85714mg
Entrapping Efficiency EE (%) = 30 X 0 .02185 X 100 0 .85714
 = 76.47 %.
==========
      
NP- 2
Weight of the nanoparticle  = 30mg
Drug content in the nanoparticle  = 0.00125mg
Added drug amount  = 0.85714mg
Entrapping Efficiency EE (%) = 30 X 0 .001255 X 100 0 . 85714
 = 4.37 %
==========
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TARGETING OF THE NANOPARTICLES TO COLON
Preparation of Eudragit RL 100 coated gelatin capsule 
Dipping method
The  different  concentrations  of  Eudragit  RL100  solutions  were 
prepared (4%. 6%, 8% and 10%) by mixing the powder Eudragit RL 100 
with  methanol  and  dichloromethane  mixture  in  a  ratio  of  1:4.  Dibutyl 
phthalate (2 % v/v) was also added to the above solution as plasticizer. 
The hard gelatin empty capsules ( size No.1) were taken and separated 
the cap and the body,  each part  is  dipped into different ratio solutions 
Eudragit RL100. Six times the procedure was repeated in a time interval of  
3 hours. The 5-Fu nanoparticles are filled in the capsules and sealed.
In Vitro Drug Release studies of the Eudragit RL 100 coated capsules
Nanoparticles equivalent to 100mg of 5-Fu were filled in a capsule 
and sealed  with Eudragit RL100  and dissolution studies carried out in 
900 ml of  pH medium at 370C in 60 rpm. The pH of the medium was 
gradually increased from 0.1 N HCl (pH1.2), Phosphate buffer pH 5.8, pH 
6.8 respectively for 2 hours each, then transferred it to pH 7.4 phosphate 
buffer until  the end of the experiment. At specific time interval 1,2….11 
hours, dissolution sample was quantified spectrophotometrically at 266nm.
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Table  5:  Eudragit RL 100 (4% w/v) In vitro  drug release 
S.No Time in minutes Percentage release
1 300 00.00
2 315 08.07 ±  0.62
3 330 28.65 ±0.83
4 345 39.85 ±0.28
5 360 44.55 ±0.59
6 375 52.21 ±0.60
7 390 58.65 ±0.70
8 405 64.86 ±0.71
9 420 77.02 ±0.72
10 435 85.75 ±0.45
11 450 96.10 ±0.46
Fig. 11 Eudragit RL 100 (4% w/v) In vitro  drug release 
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Table  6: Eudragit RL 100 (6% w/v) In vitro  drug release 
S.No Time in hours Percentage release
1 390 00.00
2 405 02.06 ±0.28
3 420 12.57 ±0.46
4 435 26.05 ±0.58
5 450 49.00 ±0.8
6 465 53.46 ±0.38
7 480 76.65 ±0.32
8 495 81.75 ±0.18
9 510 88.06 ±0.33
10 525 92.45 ±0.37
11 540 93.33 ±0.27
Fig. 12  Eudragit RL 100 (6% w/v) In vitro  drug release 
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Table 7: Eudragit RL 100 (8% w/v) In vitro drug release 
Fig. 13  Eudragit RL 100 (8% w/v) In vitro  drug release 
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Table 8 :  Eudragit RL 100 (10% w/v) In vitro  drug release 
S. No Time in hours Percentage release
1 450 00.00
2 465 07.09 ±  0.23
3 480 16.99±  0.22
4 495 43.33±  0.46
5 510 48.21±  0.19
6 525 53.43±  0.27
7 540 57.98±  0.90
8 555 64.47±  0.92
9 570 70.07±  0.95
10 585 76.05±  0.92
11 590 81.54±  0.88
12 605 88.31±  0.84
90
13 620 89.99±  0.69
Fig. 14  Eudragit RL 100 (10% w/v) In vitro  drug release 
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RESULTS AND DISCUSSION
FT-IR SPECTRAL ANALYSIS
Compatibility studies of 5-Fluorouracil, PLGA (50:50) were carried 
out by FT-IR peak matching method. The IR spectra of pure drug, polymer 
and physical mixture  (1:1) shown in  Fig 3, 4 and 5 respectively. 
The IR spectrum of physical mixture did not show any significant 
differences from those obtained for pure samples. These obtained results 
indicate that there was no positive evidence for the interaction between the 
drug and the polymer. More than hydrogen bonding (if any), which may 
have occurred between donating and accepting groups of both drug and 
polymer.
PARTICLE SIZE AND SHAPE ANALYSIS USING SEM
Scanning  Electron  Microscopy  reveals  that  all  prepared 
nanoparticles  had  a  homogeneous  solid  matrix  structure,  with  no 
evidences of crystals on the surface (Fig.10 and 10A).The PLGA loaded 
nanoparticles  with  5-Flurouracil   produced by  nanoprecipitation  method 
enabled us to get spherical,  discrete spheres with a size ranging from  
300 – 500nm.
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ENCAPSULATION EFFICIENCY STUDIES
Encapsulation  efficiency  (EE)  of  nanoparticles  was  found  to  be 
76.47% and 4.38% for the formulation NP-1 and NP-2 respectively. The 
encapsulation efficiency of a nanoparticulate carrier is mainly altered by 
the nature drug incorporated, and the method of production adopted. The 
results indicated the formulation NP-1 has a good encapsulation efficiency, 
which revealed that this drug and polymer ratio is ideal for formulations.
IN  VITRO DRUG  RELEASE  STUDIES  OF  COLON  TARGETED 
EUDRAGIT RL 100 COATED NANOPARTICLES
 The characterization of in vitro drug release from a colloidal carrier 
especially under sink condition is technically difficult to achieve. This could 
be attributed to the inability to separate successfully the particles from the 
dissolved or release drug in the sink solution due to the very small size of 
the  particles.  Attempting  to  evaluate  the  drug  release  from  colloidal 
carriers, diverse techniques have been used for example, diffusion cells, 
where  the  undiluted  colloidal  drug  carrier  is  separated  from  the  sink 
solution by porous membrane.
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As an acidic polymer Eudragit RL 100 is ionized to a greater extent 
at  higher  pH, accounting for  a  greater  degree of  hydration.  Dissolution 
study of Eudragit RL 100 coated capsules in simulated pH 1.2 and pH 5.8, 
revealed that there is no release of 5-Fu from all four different percentage 
of  Eudragit  coatings.  Eudragit  RL 100 coated capsules  are  showing  a 
good release of drug in the pH of 6.8 and 7.4. Release rate of 5-Fu form 
Eudragit RL 100 was found to be pH dependent. In four concentrations the 
10% solution used for coating the capsules were showing good release 
pattern of 5-FU in a delayed rate (Fig.14). So, the 10 % concentration of 
Eudragit  RL 100 coated capsules is suitable for colon targeting.
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SUMMARY AND CONCLUSION
The  nanoprecipitation  procedure  was  used  to  prepare 
biodegradable  nanoparticles  of  spherical  shape  and   size  range  of  
300-500 nm with  different of processing parameters,  the results of the  
in vitro release profiles of the entrapped anticancer drug from the capsule 
were  pH dependent erosion of the Eudragit RL 100 layer according to the 
different  area  of  the  intestine.  The  designed  site  specific  delivery  of  
5-Fluorouracil capsules may reduce the side effects of the drug caused by 
its absorption from the GI tract when given in conventional dosage forms.
The  results  of  this  study  clearly  indicate  that  there  was  great 
potential  in  delivery  of  5-Fluorouracil  to  the  colonic  region.  So it  is  an 
alternative  to  the  conventional  dosage  form.  However,  more  extensive 
pharmacokinetic  and  pharmacodynamic  studies  are  needed  before 
establishing colonic delivery of Eudragit coated 5-Fluorouracil capsules as 
an alternative. Eudragit RL 100 is a biocompatible polymer; we expect it to 
cause no harmful  effects if  used for prolonged periods.  This study has 
suggestes that the Eudragit  RL 100 coated capsules offer an excellent 
potential for the targeted release of drugs for colorectal cancer.
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